Gallium maltolate

Gallium maltolate (GAM) 是一种由镓 (Gallium) 和麦芽酚酸 (Maltolate) 结合而成的口服有效化合物,可激活 Hut78 细胞的氧化应激和 p53 通路;其中 Gallium 通过干扰金属蛋白酶(如铁代谢)的核心机制,既能抑制细菌生长、促进伤口愈合(如马增生性肠病、马慢性伤口感染),又能抑制肿瘤细胞增殖、诱导其凋亡 (apotosis)(如皮肤T细胞淋巴瘤、胶质细胞瘤),同时调节免疫微环境,而 Maltolate 作为一种有机配体能够增强 Gallium 的稳定性和生物利用度,因此 Gallium maltolate 可用于抗炎、抗菌、抗癌研究。
产品编号: MS-R47763 纯度: 99.93% CAS No.: 108560-70-9 分子式: C18H15GaO9 分子量: 445.03
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价

产品描述

Gallium maltolate (GAM) 是一种由镓 (Gallium) 和麦芽酚酸 (Maltolate) 结合而成的口服有效化合物,可激活 Hut78 细胞的氧化应激和 p53 通路;其中 Gallium 通过干扰金属蛋白酶(如铁代谢)的核心机制,既能抑制细菌生长、促进伤口愈合(如马增生性肠病、马慢性伤口感染),又能抑制肿瘤细胞增殖、诱导其凋亡 (apotosis)(如皮肤T细胞淋巴瘤、胶质细胞瘤),同时调节免疫微环境,而 Maltolate 作为一种有机配体能够增强 Gallium 的稳定性和生物利用度,因此 Gallium maltolate 可用于抗炎、抗菌、抗癌研究。

生物实验数据

生物活性 Gallium maltolate (GAM) is an orally effective compound formed by the combination of gallium and maltolate, which activates oxidative stress and the p53 pathway in Hut78 cells; gallium, through interfering with the core mechanisms of metalloproteins such as iron metabolism, can both inhibit bacterial growth and promote wound healing (e.g., equine proliferative enteropathy and chronic equine wound infections), and inhibit tumor cell proliferation and induce apoptosis (apotosis) (e.g., cutaneous T-cell lymphoma and glioma), while also modulating the immune microenvironment, and maltolate, as an organic ligand, enhances the stability and bioavailability of gallium, so Gallium maltolate can be used for anti-inflammatory, antibacterial, and anticancer research.
体外研究
(In Vitro)

Gallium maltolate (0-500 μM, 0-4 d) 对 HuT78 和 HH 细胞表现出剂量和时间相关的细胞毒性作用。
Gallium maltolate (0-150 μM, 8-24 h) 可诱导 Hut78 细胞凋亡,并导致细胞内氧气消耗率呈剂量依赖性降低。
Gallium maltolate (0-1 d) 会激活 Hut78 细胞的氧化应激和 p53 通路。
Gallium maltolate 对耐甲氧西林金黄色葡萄球菌 (MRSA) 菌株和非耐药金黄色葡萄球菌 (MSSA) 菌株均显示出 750 μM 的最小抑菌浓度。
Gallium maltolate (25-15000 μM) 在抗菌浓度下对皮肤细胞 (hDF) 的影响相对较小,其 IC50 值为 2220 μM。

Cell Cytotoxicity Assay

Cell Line: HuT78 and HH cells
Concentration: 100, 200, 300, 400 and 500 μM
Incubation Time: 0, 1, 2, 3 and 4 d
Result: More sensitive in HuT78 cells (complete death occurred after 3 days of treatment at 100 μM).
Observed mitochondrial function inhibition at an early stage (8 hours).
Had a relatively low toxicity to normal keratinocytes (HaCaT) and shows selective toxicity.

Apoptosis Analysis

Cell Line: HuT78 cells
Concentration: 100 μM
Incubation Time: 24 h
Result: Showed marked increases of annexin V or 7-AAD positivity.
体内研究
(In Vivo)

Gallium maltolate (400 μg/per mouse, 瘤周注射给药, 每日一次, 持续 5 天) 能有效抑制小鼠皮肤 T 细胞淋巴瘤 (CTCL) 肿瘤的生长,并创造不利于肿瘤生长的微环境。
Gallium maltolate (50 mg/kg, 经鼻胃管给药, 每两天一次, 持续 15 周) 在感染家兔中对马增生性肠炎(PEP) 的疗效似乎与 Doxycycline (MS-M54651) 相当。
Gallium maltolate (50 mg/kg, p.o., 每日一次, 用药两周,停药一周一个治疗周期) 在大鼠难治性胶质母细胞瘤 (trGBM) 异种移植模型中表现出强效的抗肿瘤作用。
Gallium maltolate (1.25 mL/wound, 0.5% 溶于石油基底, 局部给药, 一周两次共 21 天) 对马的非感染性和感染性伤口愈合具有有益作用。

Animal Model: Hut78 or HH cells induced xenograft CTCL mouse model established in C57BL/6 mice
Dosage: 400 μg/per mouse
Administration: Administered by peritumoral injection, once daily, for 5 consecutive days starting on 1st wk, 2nd wk, or 3rd wk
Result: Preventive treatment (started from the first week) was the most effective, with 60% of the mice showing no tumor formation.
Had a significant inhibitory effect on tumors that had already formed (still effective from the second and third weeks of treatment).
Significantly reduced the vascularization of tumors (CD31+ area).
Increased the chemotactic factors (CXCL10/11) induced by IFN-γ, and decreased the immunosuppressive cytokine IL-10.
Animal Model: Lawsonia intracellularis infection model established in in juvenile female rabbits (5-6 weeks)
Dosage: 50 mg/kg
Administration: By nasogastric tube, every second day for 15 weeks
Result: Was a significant inhibition of weight loss during the treatment period (8-14 days).
No significant reduction in the amount of bacterial DNA.
Did not interfere with the host's generation of protective immune response.
Alleviated the intestinal lesions, but not as effectively as with doxycycline.
Animal Model: Xenograft model of trGBM established in male and female athymic rats (180-250g)
Dosage: 50 mg/kg
Administration: Oral administration (p.o.), once daily on a two-week on, one-week off treatment cycle
Result: Significantly reduced the growth rate and delayed the progression time of the tumor.
The risk of death has decreased by 79%.
Neurological symptoms appeared later, weight remained stable and no treatment-related toxicity.
Characterized by an absence of an invasive edge and a significant reduction in both, MIB-1% and mitotic index.
Decreased the expression of pro-angiogenic markers (von Willebrand Factor and VEGF) and increased the expression of anti-angiogenic markers, such as Angiopoietin-2.
Animal Model: Equine wound with non-infected and infected healing model established in horses (mean age was 7 years and mean weight was 446 kg)
Dosage: 1.25 mL/wound, 0.5% in a petroleum base
Administration: Topical administration, twice a week for 21 days
Result: The non-infected wound area has shrunk and the granulation tissue remains flat with TGF-β increasement and MMP decreasement.
The bacterial load in the infected wound decreased, and the wound area shrank by 69% in the fourth week, with inflammation also reduced.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 445.03
分子式 C18H15GaO9
CAS No. 108560-70-9

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 0.24 mg/mL (0.54 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 2 mg/mL (4.49 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM2.2470 mL11.2352 mL22.4704 mL56.1760 mL

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础